Mab21L2 expression is considered for classification of medulloblastoma subtypes (is among the Nanostring signature genes [39]), differentially expressed in brain vs. bone metastases of breast cancer [26], and low expression of lnc-MAB21L2-1 correlated with resistant to neoadjuvant chemoradiotherapy in rectal cancer [17]. The gene discussed is MAB21L2; the disease is breast cancer.